The CAD patients were on a combination of drug therapy to lower lipid levels (statins = 83.3%), maintain blood pressure (beta-blockers = 72.2%; ACE-inhibitors/angiotensin II receptor blockers = 50%) and prevent reinfraction (anti-platelets/aspirin = 77.8%). The gene discussed is ACE; the disease is coronary artery disorder.